Edition:
United Kingdom

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

57.61USD
4:09pm GMT
Change (% chg)

$-0.65 (-1.12%)
Prev Close
$58.26
Open
$57.89
Day's High
$58.78
Day's Low
$56.72
Volume
61,313
Avg. Vol
379,274
52-wk High
$59.79
52-wk Low
$39.08

Latest Key Developments (Source: Significant Developments)

Proqr In-Licenses Worldwide Rights To Eye Drug Candidate From Ionis Pharma
Monday, 29 Oct 2018 

Oct 29 (Reuters) - ProQR Therapeutics NV ::PROQR IN-LICENSES WORLDWIDE RIGHTS TO OPHTHALMOLOGY DRUG CANDIDATE FROM IONIS PHARMACEUTICALS.PROQR THERAPEUTICS NV - HUMAN PHASE 1/2 CLINICAL TRIAL IN ADRP PATIENTS IS EXPECTED TO START IN 2019.PROQR THERAPEUTICS NV - MADE AN UPFRONT PAYMENT IN ORDINARY SHARES IN AGGREGATE AMOUNT OF $2.5 MILLION, AT $22.23 PER SHARE.PROQR THERAPEUTICS NV - ANNOUNCED SIGNING OF AN AGREEMENT WITH IONIS PHARMACEUTICALS TO LICENSE QR-1123.PROQR THERAPEUTICS - WILL ALSO MAKE FUTURE MILESTONE PAYMENTS, SOME IN EQUITY AND OTHERS IN CASH OR EQUITY AT CO'S DISCRETION.  Full Article

Ionis Pharmaceuticals - Phase 1B/2 Data Of Durvalumab Plus Danvatirsen Presented
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Ionis Pharmaceuticals Inc ::PHASE 1B/2 DATA OF DURVALUMAB PLUS DANVATIRSEN PRESENTED AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY.IONIS PHARMACEUTICALS INC - RESPONSE RATE APPROXIMATELY DOUBLED COMPARED TO PREVIOUS STUDIES WITH DURVALUMAB ALONE IN REFRACTORY HEAD AND NECK CANCER.IONIS PHARMACEUTICALS INC - DANVATIRSEN, IONIS' MOST ADVANCED GENERATION 2.5 ANTISENSE DRUG, DEMONSTRATED POTENTIAL TO TREAT INTRACTABLE CANCERS.IONIS PHARMACEUTICALS INC - ASTRAZENECA IS EVALUATING DANVATIRSEN IN A RANGE OF CANCER TYPES AS PART OF A BROADER ONCOLOGY PARTNERSHIP.  Full Article

Akcea And Ionis Receive FDA Approval Of Tegsedi (Inotersen) For The Treatment Of The Polyneuropathy Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Akcea Therapeutics Inc ::AKCEA AND IONIS RECEIVE FDA APPROVAL OF TEGSEDI (INOTERSEN) FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS.AKCEA THERAPEUTICS INC - TEGSEDI IS NOW APPROVED IN U.S., EUROPEAN UNION AND CANADA.  Full Article

Biogen Reports Qtrly Non-GAAP Earnings Per Share Of $5.80
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Biogen Inc ::BIOGEN Q2 2018 REVENUES INCREASE 9% TO $3.4 BILLION.QTRLY EARNINGS PER SHARE (EPS) ATTRIBUTABLE TO BIOGEN INC. $4.18.QTRLY NON-GAAP EARNINGS PER SHARE $5.80.Q2 EARNINGS PER SHARE VIEW $5.21, REVENUE VIEW $3.25 BILLION -- THOMSON REUTERS I/B/E/S.IN Q2 GAAP DILUTED EPS IMPACTED BY $2.84 RELATED TO COLLABORATION AGREEMENT WITH IONIS PHARMACEUTICALS, AMONG OTHERS.QTRLY TECFIDERA REVENUE $1,087 MILLION VERSUS $1,111 MILLION.ACQUIRES MUSCLE ENHANCEMENT PROGRAM FROM ALIVEGEN.QTRLY SPINRAZA REVENUE $423 MILLION VERSUS $203 MILLION.ACQUISITION FROM ALIVEGEN INCLUDES AN UPFRONT PAYMENT OF $27.5 MILLION.UPDATING ITS FULL YEAR 2018 FINANCIAL GUIDANCE.2018 REVENUE EXPECTED TO BE ABOUT $13.0 BILLION TO $13.2 BILLION.BIOGEN - AS PER DEAL, MAY PAY ALIVEGEN UP TO $535 MILLION IN ADDITIONAL POTENTIAL DEVELOPMENT, COMMERCIALIZATION MILESTONES ACROSS BOTH ASSETS & MULTIPLE INDICATIONS.2018 GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $21.80 AND $22.40.2018 NON-GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $24.90 AND $25.50.FY2018 EARNINGS PER SHARE VIEW $23.97, REVENUE VIEW $12.97 BILLION -- THOMSON REUTERS I/B/E/S.HAS ACQUIRED ALG-801 (PHASE 1A) AND ALG-802 (PRECLINICAL) FROM ALIVEGEN INC.  Full Article

Akcea And Ionis Announce Approval Of Tegsedi In The EU
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Akcea Therapeutics Inc ::AKCEA AND IONIS ANNOUNCE APPROVAL OF TEGSEDI™ (INOTERSEN) IN THE EUROPEAN UNION.AKCEA THERAPEUTICS INC - TEGSEDI'S U.S. PRESCRIPTION DRUG USER FEE ACT, OR PDUFA, DATE IS OCTOBER 6, 2018.  Full Article

Ionis And AstraZeneca Advance New Drug For NASH
Monday, 9 Apr 2018 

April 9 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS AND ASTRAZENECA ADVANCE NEW DRUG FOR NASH.IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX.IONIS PHARMACEUTICALS INC - ASTRAZENECA WILL BE RESPONSIBLE FOR FURTHER DEVELOPMENT & COMMERCIALIZATION OF IONIS-AZ6-2.5-LRX.IONIS PHARMACEUTICALS INC - AS IONIS-AZ6-2.5-LRX ADVANCES, CO MAY RECEIVE UP TO $300 MLN IN ADDITIONAL DEVELOPMENT & REGULATORY MILESTONE PAYMENTS.  Full Article

Ionis Pharmaceuticals Announces Initiation Of Clinical Study Of First Orally Delivered Antisense Drug For Treatment Of Gastrointestinal Disorders
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS PHARMACEUTICALS ANNOUNCES THE INITIATION OF A CLINICAL STUDY OF ITS FIRST ORALLY DELIVERED ANTISENSE DRUG FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS.IONIS PHARMACEUTICALS- UNDER AGREEMENT WITH JANSSEN, CO TO RECEIVE NEARLY $585 MILLION IN DEVELOPMENT, REGULATORY, SALES MILESTONE PAYMENTS & LICENSE FEES.IONIS PHARMACEUTICALS INC - EARNED $5 MILLION MILESTONE PAYMENT ASSOCIATED WITH INITIATION, ENROLLMENT IN PHASE 1 CLINICAL STUDY OF IONIS-JBI1-2.5(RX).IONIS PHARMACEUTICALS INC - JANSSEN BIOTECH IS CONDUCTING PHASE 1 STUDY.  Full Article

Biogen, Ionis Collaborate To Identify Novel Therapies To Treat Spinal Muscular Atrophy
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Biogen Inc ::BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY.BIOGEN WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF THE COLLABORATION.‍IONIS WILL RECEIVE A $25 MILLION UPFRONT PAYMENT AND WILL EARN DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS FROM BIOGEN.BIOGEN WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND COMMERCIALIZATION.ON COMMERCIALIZATION OF NOVEL THERAPIES TO TREAT SPINAL MUSCULAR ATROPHY​, BIOGEN TO PAY IONIS PERFORMANCE MILESTONES, ROYALTIES ON NET SALES.  Full Article

Ionis' License Agreement For Huntington's Disease Drug Receives Hart-Scott-Rodino Clearance
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS' LICENSE AGREEMENT FOR HUNTINGTON'S DISEASE DRUG, IONIS-HTT RX, RECEIVES HART-SCOTT-RODINO CLEARANCE.IONIS PHARMACEUTICALS INC - IONIS HAS EARNED A $45 MILLION LICENSE FEE FROM ROCHE.IONIS PHARMACEUTICALS INC - ROCHE IS NOW RESPONSIBLE FOR ALL IONIS-HTT(RX) DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES AND COSTS.  Full Article

Ionis Pharma Says Roche Has Exercised Option To License IONIS-HTT(Rx)
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS PHARMACEUTICALS LICENSES IONIS-HTT RX TO PARTNER FOLLOWING SUCCESSFUL PHASE 1/2A STUDY IN PATIENTS WITH HUNTINGTON'S DISEASE.IONIS PHARMA SAYS ROCHE HAS EXERCISED OPTION TO LICENSE IONIS-HTT(RX).IONIS PHARMACEUTICALS INC - ROCHE WILL NOW BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIAL ACTIVITIES FOR IONIS-HTT(RX).IONIS PHARMACEUTICALS INC - IN CONJUNCTION WITH DECISION TO LICENSE IONIS-HTT(RX), IONIS EARNED A $45 MILLION LICENSE FEE FROM ROCHE..  Full Article

BRIEF-Ionis Pharmaceuticals Enters New Collaboration With Partner

* IONIS ENTERS NEW COLLABORATION WITH PARTNER TO DEVELOP IONIS-FB-L RX FOR COMPLEMENT-MEDIATED DISEASES